Physician profile
Holly Mark Max
NPI 1659926855
$6,399.26
in general payments reported to CMS, 2019-2025
30 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $3,561 · 2023: $1,198 · 2024: $817 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,653.48 | 2022-2024 | Mycarelink |
| Bayer Healthcare Pharmaceuticals INC. | $538.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $454.61 | 2022-2025 | Farxiga, Breztri, Wainua |
| Janssen Pharmaceuticals, INC | $391.82 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.09 | 2022-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $265.51 | 2022 | |
| Lilly USA, LLC | $256.96 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $196.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $182.92 | 2023-2025 | Repatha |
| Esperion Therapeutics, INC. | $179.28 | 2022-2024 | Nexletol |
| Baxter Healthcare | $142.18 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $142.11 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $132.55 | 2022-2025 | Verquvo |
| Pfizer INC. | $122.90 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $91.03 | 2024-2025 | Onpattro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.43 | 2022-2023 | Lifevest |
| Atricure, INC. | $73.59 | 2022-2024 | |
| Abbott Laboratories | $71.34 | 2023-2025 | Mitraclip, Cardiomems |
| Edwards Lifesciences Corporation | $48.50 | 2023 | |
| Exact Sciences Corporation | $46.58 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Impulse Dynamics (USA) INC. | $44.54 | 2023-2024 | Optimizer, Optimizer |
| Abbvie INC. | $43.45 | 2023-2025 | |
| Scpharmaceuticals INC. | $41.16 | 2023-2024 | |
| Azurity Pharmaceuticals, INC. | $31.83 | 2024 | Edarbyclor |
| Bardy Diagnostics, INC. | $24.00 | 2022 | |
| Amarin Pharma, INC. | $20.16 | 2022 | |
| Chiesi USA, INC. | $16.45 | 2024 | Cleviprex, Kengreal |
| Corcept Therapeutics | $16.43 | 2025 | Korlym |
| Lexicon Pharmaceuticals, INC. | $15.87 | 2023 | Inpefa |
| Medicure Pharma INC. | $15.61 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Max listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.